Home » Archive

Drug Development

Drug Development, News, Syndication, Xconomy »

MediciNova Misses Primary Goal in Mid-Stage Trial of IV Asthma Drug

Posted by sandiegobiotech May 23rd, 2012 .
No Comments

It was clear that San Diego’s MediciNova (NASDAQ: MNOV) had a lot riding on the outcome of a mid-stage trial of the company’s lead drug candidate, bedoradrine sulfate. As I reported recently,…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

SD Biotech Roundup: Elevation Pharmaceuticals, BioSurplus, and More

Posted by sandiegobiotech May 17th, 2012 .
No Comments

We’re anticipating a lot of news out of a big cancer conference that begins next week in Chicago. Here is your head start. —Cancer researchers have talked for decades about finding the silver bullet…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego’s MediciNova Nears Turning Point with Lead Drug for Asthma

Posted by sandiegobiotech May 8th, 2012 .
No Comments

[Corrected 5/7/12, 5:10 pm. See below.] When Yuichi Iwaki started MediciNova in 2000, he says many mid-size pharmaceutical companies in Japan had concluded it was just too difficult to conduct their…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

AstraZeneca Reloads its Pipeline with Ardea Deal, Could be Still Hunting

Posted by sandiegobiotech April 23rd, 2012 .
No Comments

AstraZeneca (NYSE: AZN), the global pharmaceutical giant based in London, is replenishing its drug pipeline with its acquisition of San Diego’s Ardea Biosciences (NASDAQ: RDEA), which was disclosed…

[[Click headline to continue reading.]]

More...

Diagnostics, Drug Development, Drug Discovery, Featured, SDBN Blog »

San Diego’s Biotechnology Companies: Who’s Taking Off?

Posted by Lara March 8th, 2012 .
No Comments

Here at SDBN we’ve been updating our directory of 400+ San Diego biotech companies.  We were surprised to find close to 40 companies removed from the local scene – due to acquisition or shut down.  But we also found a net gain in companies, with 68 added. We’ve begun to add some of the ‘provenances’ of new companies, as well as what’s happened to those that are no longer listed, and welcome your comments and additions as well, please leave them as a comment below. Note that some companies …

More...

Drug Development, Drug Discovery, Headline, SDBN Blog, SDBN Events »

SDBN March 26th 2012 Event with Organovo

Posted by Mary Canady March 6th, 2012 .
No Comments

Organovo is an exciting San Diego biotech company with technology to create human tissue through a technique called 3D bioprinting. The tissue can be used for drug discovery and development, and the company has been included in the MIT Technology Review’s 2012 TR50 list of the world’s most innovative companies. The excitement around Organovo has grown since they recently announced funding and their stock is now publicly traded. You’ll get the chance to hear from CEO Keith Murphy at our March 26th event, he’ll give a presentation titled ‘3D Bioprinting …

More...

Drug Development, News, Syndication, Xconomy »

San Diego’s Aragon Raises $42 Million, Targets Hormone-Driven Cancers

Posted by sandiegobiotech March 5th, 2012 .
No Comments

Aragon Pharmaceuticals, a San Diego startup targeting hormone-driven cancers, has raised $42 million in a Series C financing led by a new investor, the Topspin Fund, a Long Island, NY-based firm…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Organovo Raises $6.5M, Lists on OTC, in Alternative Public Offering

Posted by sandiegobiotech February 14th, 2012 .
No Comments

Shares of San Diego-based “bio-printing” company Organovo are set to begin trading over the counter today, following a reverse merger and $6.5 million in private placement financing, which Organovo…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Amylin, Optimer, and the Economy

Posted by sandiegobiotech February 3rd, 2012 .
No Comments

—San Diego’s Amylin Pharmaceuticals says Bydureon, its new once-a-week drug for treating Type 2 diabetes can hit the market as early as next month, after the FDA cleared Bydureon. The FDA rejected…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Angry at the Genome

Posted by sandiegobiotech January 24th, 2012 .
No Comments

In 2004, I was an enthusiastic postdoctoral researcher in Eric Lander’s lab at the Broad Institute, with the job I had dreamed of since I was 10 years old. Growing up in Paducah, KY, I read Isaac…

[[Click headline to continue reading.]]

More...